ZAHI TOUMA

Summary

Affiliation: University of Toronto
Location: Toronto, Canada

Publications

  1. ncbi TNF polymorphisms in Lebanese patients with Behçet's disease
    T K Arayssi
    Clin Exp Rheumatol 26:S130-1. 2008
  2. ncbi CTLA-4 gene variants are not associated with Behçet's disease or its clinical manifestations
    Z Touma
    Clin Exp Rheumatol 26:S132. 2008
  3. ncbi SLEDAI-2K for a 30-day window
    Z Touma
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada
    Lupus 19:49-51. 2010
  4. ncbi TNF polymorphisms in patients with Behçet disease: a meta-analysis
    Zahi Touma
    Department of Internal Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    Arch Med Res 41:142-6. 2010
  5. ncbi Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus
    Z Touma
    University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Canada
    Clin Exp Rheumatol 28:525-31. 2010
  6. ncbi Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis
    Zahi Touma
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:69-78. 2011
  7. ncbi Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time
    Dominique Ibanez
    University of Toronto Lupus Clinic and Centre for Prognosis Studies in the Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:60-3. 2011
  8. ncbi Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Room 1E 409, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
    J Rheumatol 38:275-84. 2011
  9. ncbi SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
    Z Touma
    Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
    Lupus 20:67-70. 2011
  10. ncbi Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada
    J Rheumatol 38:868-73. 2011

Collaborators

Detail Information

Publications24

  1. ncbi TNF polymorphisms in Lebanese patients with Behçet's disease
    T K Arayssi
    Clin Exp Rheumatol 26:S130-1. 2008
  2. ncbi CTLA-4 gene variants are not associated with Behçet's disease or its clinical manifestations
    Z Touma
    Clin Exp Rheumatol 26:S132. 2008
  3. ncbi SLEDAI-2K for a 30-day window
    Z Touma
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada
    Lupus 19:49-51. 2010
    ..Thus SLEDAI-2K 30 days is similar to SLEDAI-2K 10 days, both in patients in remission and with a spectrum of disease activity levels. SLEDAI-2K 30 days may now be used to describe disease activity over the previous 30 days...
  4. ncbi TNF polymorphisms in patients with Behçet disease: a meta-analysis
    Zahi Touma
    Department of Internal Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    Arch Med Res 41:142-6. 2010
    ..The aim of this meta-analysis is to examine the association between polymorphism in the TNF gene at the locations -308, -238, -863, -857 and -1031 and Behçet's disease...
  5. ncbi Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus
    Z Touma
    University of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Canada
    Clin Exp Rheumatol 28:525-31. 2010
    ..To determine whether immunological burden of autoantibodies as reflected by the number of cumulative antibodies present at inception and after 3 and 5 years is associated with or predicts subsequent disease activity and damage in lupus...
  6. ncbi Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis
    Zahi Touma
    University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:69-78. 2011
    ..to systematically review the efficacy and safety of mycophenolic acid and mycophenolate mofetil (MMF) compared to cyclophosphamide (CYC) for the induction treatment of lupus nephritis (LN)...
  7. ncbi Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time
    Dominique Ibanez
    University of Toronto Lupus Clinic and Centre for Prognosis Studies in the Diseases, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Rheumatol 38:60-3. 2011
    ..adjusted mean Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; AMS) measures lupus disease activity over time. Our aim was to determine optimal visit frequency for calculating AMS...
  8. ncbi Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Room 1E 409, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada
    J Rheumatol 38:275-84. 2011
    ..To describe the development and validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index 50 (SRI-50), an index to measure improvement in disease manifestations on followup visits...
  9. ncbi SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation
    Z Touma
    Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
    Lupus 20:67-70. 2011
    ..SLEDAI-2K 30 days was validated against SLEDAI-2K 10 days in a longitudinal evaluation over 1 year. We recommend the use of SLEDAI-2K 30 days in clinical studies and clinical trials...
  10. ncbi Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada
    J Rheumatol 38:868-73. 2011
    ....
  11. ncbi Long-delayed onset of chest wall pain defining a patient with SAPHO syndrome
    Zahi Touma
    Division of Rheumatology, Department of Internal Medicine, American University of Beirut Medical Center, Riad Solh Cairo Street, Beirut, Lebanon
    J Clin Rheumatol 13:338-40. 2007
    ..This case report emphasizes the long duration that can lapse between onset of initial skin manifestations and musculoskeletal symptoms to define SAPHO syndrome...
  12. ncbi Successful treatment of cardiac involvement in dermatomyositis with rituximab
    Zahi Touma
    American University of Beirut Medical Center, Department of Internal Medicine, Division of Rheumatology, PO Box 11 0236 Riad El Solh, Beirut 1107 2020, Lebanon
    Joint Bone Spine 75:334-7. 2008
    ..The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease...
  13. ncbi Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept
    I Uthman
    Rheumatology (Oxford) 44:1200-1. 2005
  14. ncbi Response of deep cutaneous vasculitis to infliximab
    Imad W Uthman
    J Am Acad Dermatol 53:353-4. 2005
  15. ncbi Successful retreatment with infliximab in patients with prior severe infusion reactions
    Imad Uthman
    Division of Rheumatology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    Clin Rheumatol 25:540-1. 2006
    ....
  16. ncbi Endobronchial stenting for respiratory complications in relapsing polychondritis
    Ossama Abbas
    Department of Internal Medicine, American University of Beirut Medical Center, Cairo St, Hamra, P O Box 11 0236, Beirut, Lebanon
    Clin Rheumatol 26:271-3. 2007
    ..Despite an aggressive antibiotic regimen, the patient's pneumonia did not improve until bronchial stenting 4 months later...
  17. ncbi Successful treatment of Sjogren's syndrome with rituximab
    Z Touma
    Scand J Rheumatol 35:323-5. 2006
  18. ncbi Cardiac sarcoidosis responding to monotherapy with infliximab
    Imad Uthman
    Department of Internal Medicine, Faculty of Medicine, American University of Beirut Medical Center, P O Box 113 6044, Hamra Street, Beirut, 1103 2090, Lebanon
    Clin Rheumatol 26:2001-3. 2007
    ..Infliximab may be considered as an alternative first-line therapy in sarcoidosis with serious organ involvement...
  19. ncbi Family history of lymphoma and risk for solid tumors in patients with Sjogren's syndrome
    Zahi Touma
    Department of Internal Medicine, Division of Rheumatology, American University of Beirut Medical Center, 3 Dag Hammarskjold Plaza 8th floor, New York, NY 10017 2303, USA
    Rheumatol Int 28:87-8. 2007
    ..Herein we report two cases of primary Sjogren's syndrome complicated by breast and lung cancer and who have a strong family history for lymphoproliferative diseases...
  20. ncbi The use of TNF-alpha blockers in Cogan's syndrome
    Zahi Touma
    Rheumatol Int 27:995-6. 2007
  21. ncbi Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T
    Z Touma
    Department of Internal Medicine, Division of Rheumatology, American University of Beirut Medical Center, New York, NY 10017 2303, USA
    Lupus 16:517-20. 2007
    ..We describe an unusual case of longitudinal myelitis and ischemic stroke in the presence of homozygous prothrombin G20210A, heterozygous MTHFR 677T mutations and the absence of antiphospholipid antibodies in a young woman with SLE...
  22. ncbi Oral bisphosphonates in treatment of transient osteoporosis
    L Kibbi
    Department of Internal Medicine, Division of Rheumatology, American University of Beirut Medical Center, New York, NY, USA
    Clin Rheumatol 27:529-32. 2008
    ..Herein, we describe two cases of transient osteoporosis of the hip and one case of transient osteoporosis of the knee where the use of oral bisphosphonates provided successful objective and subjective outcome...
  23. ncbi Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire
    Zahi Touma
    Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto, Ontario, Canada
    BMC Med Res Methodol 11:52. 2011
    ..Exploratory Factor Analysis (EFA) was used to assess the dimensionality of the scale items. External construct validity was examined by correlating Arabic BD-QoL with the severity score, ADL and IADL...